Translating the Human CANTAB Touchscreen Based Tasks to Evaluate Learning and Memory in Mouse Models of Down Syndrome
Preprint
Abstract
Humans with Down syndrome (DS) exhibit hippocampal learning deficits in the Cambridge Neuropsychological Test Automated Battery (CANTAB). Here we translated the CANTAB Visual Discrimination (VD) and Extinction tasks to investigate hippocampal learning and cortical inhibitory control in the Dp(16)1/Yey, Ts65Dn and Ts1Cje mouse models of DS. No food or water restriction was used prior to testing. The number of days to reach 70% correct answers and percent of correct responses were analyzed. All Dp(16)1/Yey, Ts1Cje and WT mice reached Stage 5 of pre-training. No differences between genotypes were found in percent of correct responses. Five Ts65Dn and one WT animals reached Stage 5 and only one Ts65Dn mouse reached VD. Ts1Cje mice took longer (17.86±3.19 days) to move to VD vs. WT (11.44±1.96 days, P =0.09). There were no differences between Dp(16)1/Yey and WT mice. At VD, the average percent of correct answers was significantly lower in Dp(16)1/Yey (22.70±1.93%) and Ts1Cje (34.39±1.98%) compared to WT littermates (32.18±1.49% and 41.11±1.45%, respectively, P ad libitum access to food and water. In conclusion, we were able to apply human cognitive tests to evaluate hippocampal learning and cortical inhibitory control in three mouse models of DS. These studies demonstrate significant cognitive differences between strains. Future experiments will evaluate whether food restriction and/or pre- and postnatal therapy decreases the time intervals to achieve training mile.Keywords
This publication has 41 references indexed in Scilit:
- Challenges and Opportunities for Translation of Therapies to Improve Cognition in Down SyndromeTrends in Molecular Medicine, 2020
- Pharmacological interventions to improve cognition and adaptive functioning in Down syndrome: Strides to dateAmerican Journal of Medical Genetics Part A, 2017
- Changing Paradigms in Down Syndrome: The First International Conference of the Trisomy 21 Research SocietyMolecular Syndromology, 2016
- Safety and efficacy of cognitive training plus epigallocatechin-3-gallate in young adults with Down's syndrome (TESDAD): a double-blind, randomised, placebo-controlled, phase 2 trialThe Lancet Neurology, 2016
- Prenatal treatment of Down syndromeCurrent Opinion in Obstetrics and Gynecology, 2014
- The NIH Toolbox Cognition Battery: Results from a large normative developmental sample (PING).Neuropsychology, 2014
- Epigallocatechin‐3‐gallate, a DYRK1A inhibitor, rescues cognitive deficits in Down syndrome mouse models and in humansMolecular Nutrition & Food Research, 2013
- I. NIH TOOLBOX COGNITION BATTERY (CB): INTRODUCTION AND PEDIATRIC DATAMonographs of the Society for Research in Child Development, 2013
- Prospects for Improving Brain Function in Individuals with Down SyndromeCNS Drugs, 2013
- Developmental Defects in Trisomy 21 and Mouse ModelsThe Scientific World Journal, 2006